Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma
Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma
复制标题
血清 microRNA 是有前途的弥漫性大 B 细胞淋巴瘤的新型生物标志物
DOI：
10.1007/s00277-011-1350-9
复制
发表时间：
2012-04-01
影响因子：
3.5
通讯作者：
Li, Jian-Yong
中科院分区：
文献类型：
--
作者：
Fang, Cheng;Zhu, Dan-Xia;Li, Jian-Yong
MicroRNAs （miRNAs）是在包括癌症在内的许多疾病类型中不受调控的调控RNA分子。最近，mirna作为癌症诊断的标记物显示出了希望。本研究的目的是探讨血清mirna是否可以作为弥漫性大B细胞淋巴瘤（DLBCL）检测的生物标志物。我们使用实时定量逆转录聚合酶链反应（qRT-PCR）测量了DLBCL患者和健康对照血清样本中mirna （miR-15a、miR-16-1、miR-21、miR-29c、miR-34a、miR-155和miR-223）的水平。我们在这里表明，mirna以非常稳定的形式存在于人血清中。其中4种mirna （miR-15a、miR-16-1、miR-29c、miR-155）在DLBCL血清中较正常对照组显著升高（P< 0.05）， miR-34a在DLBCL血清中较正常对照组显著下调（P< 0.05）。受试者工作特征分析显示，miR-15a、miR-16-1、miR-29c、miR-34a和miR-155的曲线下面积分别为0.7722、0.7002、0.6672、0.8538和0.7157。在截断值为0.0006时，miR-15a的敏感性为80%，特异性为76%；在截断值为0.0886时，miR-16-1的敏感性为94%，特异性为51%；在截断值1.395时，miR-34a的敏感性为100%，特异性为70%；在截断值为0.0022时，miR-155的敏感性为83%，特异性为65%。总之，这些数据表明，血清mirna作为诊断DLBCL的新型无创生物标志物可能是有用的工具。
MicroRNAs (miRNAs) are regulatory RNA molecules that are deregulated in many disease types, including cancer. Recently, miRNAs have shown promise as markers for cancer diagnosis. The aim of this study was to investigate whether serum miRNAs can be used as biomarkers for the detection of diffuse large B cell lymphoma (DLBCL). We measured the levels of miRNAs (miR-15a, miR-16-1, miR-21, miR-29c, miR-34a, miR-155, and miR-223) in serum samples from patients with DLBCL and healthy controls using real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR). We show here that miRNAs are present in human serum in a remarkably stable form. Four of miRNAs (miR-15a, miR-16-1, miR-29c, and miR-155) were significantly elevated in DLBCL serum when compared with normal controls (P< 0.05), while miR-34a was downregulated in DLBCL serum when compared with controls (P< 0.05). Receiver operating characteristic analyses reflects strong discriminating DLBCL from controls, with area under the curves of 0.7722, 0.7002, 0.6672, 0.8538, and 0.7157 for miR-15a, miR-16-1, miR-29c, miR-34a, and miR-155, respectively. At the cut-off value of 0.0006 for miR-15a, the sensitivity was 80% and the specificity was 76%; at the cut-off value of 0.0886 for miR-16-1, the sensitivity was 94% and the specificity was 51%; at the cut-off value of 1.395 for miR-34a, the sensitivity was 100% and the specificity was 70%; at the cut-off value of 0.0022 for miR-155, the sensitivity was 83% and the specificity was 65%. In conclusion, these data suggest that serum miRNAs are potentially useful tools as novel noninvasive biomarker for the diagnosis of DLBCL.